We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
- Recent ARWR Stock Price: $36.12
- Yearly Gain for ARWR stock: 6.19%
- Market Cap for ARWR stock: $3.74B
- P/E Ratio for ARWR stock: -24.511
Will ARWR's stock price go up? Is there an accurate ARWR stock forecast available?
In addition, TradingView issued a Buy rating for ARWR stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARWR stock.
Other analysts covering ARWR include:
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $ 59 on 4 days ago
- Keay Nakae of Chardan Capital issued a Buy rating with the price target of $ 60 on 4 days ago
- Luca Issi of RBC Capital issued a Buy rating with the price target of $ 60 on 4 days ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 55 on 4 days ago
If you are wondering if ARWR is a good stock to buy, here are 3rd party ratings for ARWR stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Arrowhead Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARWR stock: Very Bullish
- Blogger Consensus for ARWR stock: Bullish
- Media Buzz for ARWR stock: High
- Insider Signal for ARWR stock: Negative
- Investor Sentiment for ARWR stock: Positive
- Hedge Fund signal for ARWR stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ARWR stock including scouring the social networks like ARWR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARWR stock chart >>
Summary: Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.
- Recent CSTL Stock Price: $14.72
- Yearly Gain for CSTL stock: -45.89%
- Market Cap for CSTL stock: $311.22M
- P/E Ratio for CSTL stock: -4.3
Will CSTL's stock price go up? Is there an accurate CSTL stock forecast available?
In addition, TradingView issued a Sell rating for CSTL stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on CSTL stock.
Other analysts covering CSTL include:
- Catherine Ramsey Schulte of Robert W. Baird issued a Buy rating with the price target of $ 25 on 1 day ago
- Paul Knight of KeyBanc issued a Buy rating with the price target of $ 37 on 1 day ago
- Thomas Flaten of Lake Street issued a Buy rating with the price target of $ 32 on 1 day ago
- Puneet Souda of SVB Securities issued a Buy rating with the price target of $ 35 on 1 day ago
If you are wondering if CSTL is a good stock to buy, here are 3rd party ratings for CSTL stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 39% (98 out of 250)
What is the sentiment on the street regarding Castle Biosciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for CSTL stock: Very Bullish
- Blogger Consensus for CSTL stock: Bullish
- Media Buzz for CSTL stock: Very High
- Insider Signal for CSTL stock: ―
- Investor Sentiment for CSTL stock: ―
- Hedge Fund signal for CSTL stock: Neutral
The stock market is extremely volatile, and you need to do your own research on CSTL stock including scouring the social networks like CSTL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CSTL stock chart >>
Summary: Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
- Recent MRK Stock Price: $110.01
- Yearly Gain for MRK stock: 29.70%
- Market Cap for MRK stock: $287.01B
- P/E Ratio for MRK stock: 22.09
Will MRK's stock price go up? Is there an accurate MRK stock forecast available?
In addition, TradingView issued a Sell rating for MRK stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRK stock.
Other analysts covering MRK include:
- Mara Goldstein of Mizuho Securities issued a Buy rating with the price target of $ 130 on 22 hours ago
- Carter Gould of Barclays issued a Buy rating with the price target of $ 130 on 1 day ago
- Geoff Meacham of Bank of America Securities issued a Buy rating with the price target of $ 130 on 2 days ago
- Evan Seigerman of BMO Capital issued a Hold rating with the price target of $ 102 on 2 days ago
If you are wondering if MRK is a good stock to buy, here are 3rd party ratings for MRK stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 26% (66 out of 250)
What is the sentiment on the street regarding Merck & Company? (Current ratings compiled by TipRanks.com)
- News Sentiment for MRK stock: Very Bullish
- Blogger Consensus for MRK stock: Bullish
- Media Buzz for MRK stock: Low
- Insider Signal for MRK stock: Very Negative
- Investor Sentiment for MRK stock: Negative
- Hedge Fund signal for MRK stock: Positive
The stock market is extremely volatile, and you need to do your own research on MRK stock including scouring the social networks like MRK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MRK stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
